Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy

JAMA Internal Medicine

Volumn 173, Issue 12, 2013, Pages 1136-1143

  Goldin, Gregg H ^a   Sheets, Nathan C ^a   Meyer, Anne Marie ^b   Kuo, Tzy Mey ^b   Wu, Yang ^b   Stürmer, Til ^b   Godley, Paul A ^b   Carpenter, William R ^b   Chen, Ronald C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; ERECTILE DYSFUNCTION; GASTROINTESTINAL DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE REDUCTION; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINE INCONTINENCE;

AGED; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; HUMANS; MALE; POSTOPERATIVE PERIOD; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 84879557787     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.1020     Document Type: Article

References (47)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29(12):1517-1524.
3. Institute for Clinical and Economic Review. Management Options for Low-Risk Prostate Cancer: A Report on Comparative Effectiveness and Value. Boston, MA: Institute for Clinical and Economic Review; 2009.
4. Ratner R, Eden J, Wolman D, Greenfield S, Sox H, eds. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: Institute of Medicine; 2009:107.
5. Carreyrou J, Tamman M. A device to kill cancer, lift revenue. Wall Street Journal. December 7, 2010. http://online.wsj.com/article/ SB10001424052748703904804575631222900534954.html. Accessed January 19, 2013.
6. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611-1620.
7. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924-2930.
8. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956-962.
9. Bolla M, van Poppel H, Collette L, et al European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572-578. (Pubitemid 41140332)
10. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11):1325-1332. (Pubitemid 38541647)
11. Swindle P, Eastham JA, Ohori M, et al. Do margins matter? the prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2005;174(3):903-907. (Pubitemid 41140626)
12. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74. (Pubitemid 350251041)
13. Dearnaley DP, Sydes MR, Graham JD, et al; RT01 Collaborators. Escalateddose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475-487. (Pubitemid 46805903)
14. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
15. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124-1129. (Pubitemid 351296130)
16. Bekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e325-e334. doi:10.1016/j.ijrobp.2011.02.006.
17. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(3):685-691.
18. Lips I, Dehnad H, Kruger AB, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys. 2007;69(3):656-661. (Pubitemid 47418401)
19. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302(14):1557-1564.
20. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88(3-4):166-173. (Pubitemid 26065828)
21. Lowrance WT, Elkin EB, Jacks LM, et al. Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol. 2010;183(4):1366-1372.
22. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164. (Pubitemid 40096612)
23. Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys. 2010;76(3):755-760.
24. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008;71(4):1065-1073.
25. Giordano SH, Lee A, Kuo YF, Freeman J, Goodwin JS. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer. 2006;107(2):423-432. (Pubitemid 44036573)
26. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156. (Pubitemid 43987579)
27. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550-559. (Pubitemid 40692720)
28. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253-259.
29. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-447.
30. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
31. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
32. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158(3):280-287. (Pubitemid 36944422)
33. Williams SB, Gu X, Lipsitz SR, et al. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011;117(21):4846- 4854.
34. AlDuhaiby EZ, Breen S, Bissonnette JP, et al. A national survey of the availability of intensity-modulated radiation therapy and stereotactic radiosurgery in Canada. Radiat Oncol. 2012;7:18. doi:10.1186/1748-717X-7-18.
35. Mayles WP; Radiotherapy Development Board. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol (R Coll Radiol). 2010;22(8):636-642.
36. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250- 1261. (Pubitemid 351439226)
37. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27(24):3916-3922.
38. Leff B, Finucane TE. Gizmo idolatry. JAMA. 2008;299(15):1830-1832. (Pubitemid 351549976)
39. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol . 2010;28(7):1106-1111.
40. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097-1105. (Pubitemid 34787842)
41. Koontz BF, Das S, Temple K, et al. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. Med Dosim. 2009;34(3):256-260.
42. Digesu C, Cilla S, De Gaetano A, et al. Postoperative intensity modulated radiation therapy in high risk prostate cancer: a dosimetric comparison. Med Dosim. 2011;36(3):231-239.
43. Pinkawa M, Siluschek J, Gagel B, et al. Postoperative radiotherapy for prostate cancer: evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther Onkol. 2007;183(1):23-29. (Pubitemid 46144102)
44. Goenka A, Magsanoc JM, Pei X, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol. 2011;60(6):1142-1148.
45. Goenka A, Magsanoc JM, Pei X, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys. 2012;84(1):112-118.
46. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329-2335. (Pubitemid 44749360)
47. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002;40(8)(suppl):IV-62-IV-68.